Paper Details

  1. Home
  2. Paper Details

Managing anemia in the critically ill patient.

Author: DastaJoseph F, HassanErkan, JacobiJudith, RudisMaria I

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Anemia is common in critically ill patients and is caused by blood loss and reduced red blood cell production. While blood transfusions are the standard treatment, there is debate about the ideal hemoglobin levels for transfusion. Alternatives to transfusions include minimizing blood draws, using erythropoietic agents to stimulate red blood cell production, and exploring new oxygen-carrying solutions. More research is needed to determine the best approach for managing anemia in critical care settings.
Paper Details　
Original Abstract of the Article :
Anemia of critical illness is a multifactorial condition caused by phlebotomy, ongoing blood loss, and inadequate production of red blood cells. It occurs early in the course of critical illness. Although red blood cell transfusion is the treatment of choice for immediate management of anemia in the...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1592/phco.24.2.229.33135

データ提供：米国国立医学図書館（NLM）

Navigating the Shifting Sands of Anemia in Critical Illness

Critical illness, a complex and often unpredictable journey, can lead to anemia due to a myriad of factors, including blood loss and impaired red blood cell production. This research explores the multifaceted nature of anemia in critically ill patients, highlighting the challenges of managing this condition. The authors discuss various treatment options, including blood transfusions, blood conservation tools, and erythropoietic agents, each with its own set of advantages and disadvantages. The study emphasizes the importance of careful patient selection for erythropoietic agents, considering both clinical outcomes and economic factors.

Anemia in Critical Illness: A Complex Landscape

This research sheds light on the intricacies of anemia in critical illness, a condition that can significantly impact patient outcomes. The study underscores the importance of a multidisciplinary approach to managing anemia, taking into account both the patient's clinical status and the potential economic implications of various treatment options. It highlights the need for further research to optimize treatment strategies and improve patient outcomes.

Anemia in Critical Illness: Navigating the Desert of Complexity

Anemia in critical illness is like a mirage in the desert—it can be a deceptive and potentially dangerous condition. Understanding the complex interplay of factors contributing to anemia in critically ill patients is essential for effective management. This research offers a valuable guide for clinicians navigating the challenges of anemia in critical illness, ensuring patients receive appropriate care and maximizing their chances of recovery.

Dr. Camel's Conclusion

Anemia in critical illness is a challenging landscape, requiring clinicians to navigate a complex terrain of factors and treatment options. This research provides valuable insights into the intricate nature of anemia in critical illness, emphasizing the need for a multidisciplinary approach to ensure optimal patient care. It highlights the importance of considering both clinical outcomes and economic implications in the management of anemia in this vulnerable patient population.

Date :
  1. Date Completed 2004-07-28
  2. Date Revised 2019-09-17
Further Info :

Pubmed ID

14998223

DOI: Digital Object Identifier

10.1592/phco.24.2.229.33135

Related Literature

Article Analysis
・Effective treatment of anemia
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.